Veru (VERU) Stock: Buy, Sell, or Hold?
VERU - Veru Inc.
$2.44
-0.06 (-2.40%)
▼
5d:
-7.92%
30d:
-10.95%
90d:
-25.15%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 10, 2026
0d
Get Alerted When VERU Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
ℹ️ NEUTRAL: VERU is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
ℹ️ NEUTRAL: VERU is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: VERU is currently trading at $2.44, which is considered fair relative to its 30-day fair value range of $2.43 to $2.77.
Technical Outlook: Technically, VERU is showing sideways momentum. The price is currently testing key support at $2.43. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: VERU scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $24.50 (+904.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, VERU is showing sideways momentum. The price is currently testing key support at $2.43. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: VERU scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $24.50 (+904.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$2.43 -
$2.77
Company Quality Score
45/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
50.0%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (33/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 904.1% below Wall St target ($24.50)
- WARNING: Composite score 45/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$2.43 -
$2.77
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$2.43
Resistance Level
$2.85
Current Trend
Sideways
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.48
Wall Street Target
$24.50
(+904.1%)
Revenue Growth (YoY)
18.3%
Share & Embed Analysis
Last updated: September 13, 2026 7:27 AM ET
Data refreshes hourly during market hours. Next update: 8:27 AM
Data refreshes hourly during market hours. Next update: 8:27 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is VERU showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 58 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 56 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 45 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 60 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$109 | 57 HOLD |
